Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


How Can We Screen for and Identify Tardive Dyskinesia?

Listen to 2 thought leaders in the psychiatry field discuss the importance of screening for tardive dyskinesia in patients receiving antipsychotics, including clinical pearls for identification in various clinical settings.

Greg W. Mattingly, MD
Jonathan M. Meyer, MD
Released: July 13, 2022

In this first of 6 podcast episodes on tardive dyskinesia (TD), Drs Greg W. Mattingly and Jonathan M. Meyer have a discussion on identifying TD in clinical practice—including how to effectively screen patients during telehealth appointments. They cover who should be screened and how often, informal vs formal screening, and the valuable insight that family/caregiver reports can provide in the identification process. Additional conversation sheds light on differentiating TD from other movement disorders, including tics and tremors, and the role of primary care and other specialty providers in helping to identify TD. The experts round out the podcast with a focus on the impact of TD on both patient and caregiver quality of life—even mild TD can have an enormous influence over emotional, social, and mental well-being—bringing home the point that screening for and identifying TD early on is very important for patient outcomes.

Information on this Educational Activity


Greg W. Mattingly, MD

Associate Clinical Professor
Washington University School of Medicine
St Louis, Missouri
Midwest Research Group
St. Louis, Missouri

Greg W. Mattingly, MD: consultant: AbbVie, Acadia, Alkermes, Axsome, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Otsuka, Redax, Roche, Rhodes, Sage, Shire, Sunovion, Supernus, Takeda, Teva, Trispharma; researcher: AbbVie, Acadia, Alkermes, Avanir, Axsome, Boehringer Ingelheim, Emalex, Janssen, Medgenics, NLS-1 Pharma AG, Redax, Roche, Sage, Shire, Sunovion, Supernus, Takeda, Teva; non-CME/CE services: AbbVie, Alkermes, Eisai, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Trispharma.
Jonathan M. Meyer, MD

Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

Jonathan M. Meyer, MD: consultant: Alkermes, Intra-Cellular Therapies, Karuna, Neurocrine, Noven, Otsuka America Inc., Sunovion Pharmaceuticals, Teva Pharmaceuticals.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Neurocrine Biosciences, Inc.

Related Content

Information on the utility of the AIMS in clinical practice for TD, including telehealth, from Clinical Care Options (CCO)

Leslie Citrome, MD, MPH Released: August 16, 2022

Read about a patient’s experience with bipolar disorder and reaching recovery, from Clinical Care Options (CCO)

person default Katherine Ponte, JD, MBA, CPRP Released: August 12, 2022

Charles DeBattista, MD Amber Hoberg, PMHNP Greg W. Mattingly, MD Released: August 1, 2022

Greg W. Mattingly, MD Released: July 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings